Table 3:
Clinical and laboratory criteria of transplant-associated thrombotic microangiopathy (TA-TMA) and complications after autologous hematopoietic cell transplant (aHCT)
| TMA (n= 10) |
No TA-TMA (n= 143) |
p-valuea | |
|---|---|---|---|
| Schistocytes present on peripheral smear | 9 (90%) | 24 (17%) | <0.001 |
| Number of RBC transfusions following aHCT | |||
| • Weeks 0-4 | 5.5 [2-10] | 2 [0-16] | 0.0003 |
| • Weeks 5-8 | 2 [0-5] | 0 [0-6] | <0.0001 |
| Number of platelet transfusions following aHCT | |||
| • Weeks 0-4 | 16.5 [9-43] | 7 [1-32] | 0.0002 |
| • Weeks 5-8 | 5.5 [0-15] | 0 [0-22] | <0.0001 |
| Proteinuria | 10/10 (100%) | 19/83 (23%) | <0.001 |
| Hemoglobinuria | 10/10 (100%) | 18/83 (22%) | <0.001 |
| Creatinine | |||
| • Increased by 50% | 5/7 (71%) | 53/100 (53%) | 0.45 |
| • Increased by 100% | 5/7 (71%) | 19/95 (21%) | 0.007 |
| Scheduled anti-hypertensives | 9/10 (90%) | 6/139 (4%) | <0.001 |
| Total bilirubin | 2.2 [1.1-16.3] | 0.9 [0.2-37.6] | 0.003 |
| SOS diagnosis | 3 (30%) | 35 (25%) | 0.71 |
| Infection during transplant hospitalization | |||
| • Viral | 3 (30%) | 20 (14%) | 0.18 |
| • Bacterial | 5 (50%) | 31 (22%) | 0.06 |
| • Fungal | 0 (0%) | 10 (7%) | 1.0 |
| ICU transfer | 5 (50%) | 19 (13%) | 0.009 |
| Initial hospital LOS (days) | 47.5 [27-0103] | 30 [6-101] | 0.005 |
| Delay or change in next therapy | 9/10 (90%) | 52/136 (39%) | 0.002 |
This table includes the total number of transplants, thus patients who underwent tandem transplants are included twice, with data from each transplant being reported as unique events. Data presented as number of patients (%) with denominator written if different than total sample size (n) for the column for categorical variables and as median [range] for continuous variables.
Continuous variables were compared using the Wilcoxon rank-sum test and categorical variables using the Fisher’s exact test.
Abbreviations: ICU- intensive care unit, LOS- length of stay, RBC- red blood cells, SOS- sinusoidal obstruction syndrome